Objectives: to investigate the effects of proton pump inhibitors (PPis) on the insulin-like-growth factor 1(igF-1) system in the elderly. Design: cross-sectional. Setting: inCHianti study. Participants: 938 older subjects (536 women, 402 men, mean age 75.7±7.4 years). Measurements: complete data on age, sex, BMi, liver function, medications, dietary intake, igF-1, igF-binding protein-1 and -3 (igFBP-1, igFBP-3). Results: Participants were categorized by PPi use, identifying 903 PPi non users and 35 users. after adjusting for age, male PPi users (107.0 ± 69.6 vs 127.1 ± 55.8, p<0.001) and female PPi users (87.6 ± 29.1 vs 107.6 ± 52.3, p=0.03) had lower igF-1 levels than non-users. igFBP-1 levels were similar in the two groups in both sexes. in whole population, after adjustment for age and sex, PPi users had lower igF-1 levels 81.9 [61.1-113.8] than nonusers 110 [77.8-148.6], p=0.02. after further adjustment for BMi, albumin, liver function, C-reactive protein, interleukin-6, number of medications, aCe-inhibitors use, caloric intake, protein intake, physical activity, glycemia, and igFBP-1, the use of PPis remained significantly and negatively associated with igF-1 levels (β±Se=-19.60±9.83, p=0.045). Conclusion: use of PPis was independently and negatively associated with igF-1 levels.
Introduction
the widespread use of proton pump inhibitors (PPis) drugs was gradually increased in the last two decades, especially in older people (1) . recent studies suggest that PPis may be overused or inappropriately prescribed in 25% to 81% of elderly patients taking these drugs (2) . additionally, recent studies raised concerns about the potential increased risk of fractures (3), clostridium difficile infections (4) , and community-acquired pneumonia (1) in relation to long term use of PPis. We recently found that long-term use of high dose PPis is associated with increased risk of 1-year mortality in older patients discharged from acute hospitals (5) . among potential underlying mechanisms explaining such detrimental effects, the suppression of gastric acidity and the interference with adsorption of macronutrients (protein) (6) , and micronutrients (non-heme iron, calcium, magnesium) (7) have been advocated, but other causes cannot be excluded.
nutritional intake is an important regulator of plasma insulin-like growth Factor-1 (igF-1) levels. in humans, igF-1 plasma concentrations are reduced by few days of fasting, and their subsequent normalization depends on the adequacy of energy and protein content in the refeeding diet (8) . Low igF-1 levels are also found during obesity, metabolic syndrome and diabetes, suggesting that igF-1 may be a sensitive marker of malnutrition rather than just a regulator of cell growth, differentiation, apoptosis and transformation. the igF-1 bioactivity is modulated by more than six specific high affinity binding proteins (igFBPs), which regulate and propagate igF-1 actions in several tissues. an in-vitro study of human hepatocarcinoma Hepg2 cells has shown that omeprazole can stimulate the induction of insulin-Like growth Factor Binding Protein-1 (igFBP-1), through human aryl Hydrocarbon receptor (hahr) activation, in an apparent non ligand-binding manner. omeprazole, at a concentration usually used by subjects on PPi therapy, can alter igFBP-1 expression and may influence igFBP-1-dependent physiological processes (9) . on this basis, it could be hypothesized that PPis exert their negative effects on nutritional status by interfering with igF-1 system. However, the relationship between PPi use and igF-1 system in humans has never been investigated until now. therefore, the aim of our study was to test the relationship between use of PPis and igF-1 system in older people.
Methods
to address this hypothesis we used data from the inCHianti study. this is an epidemiological, populationbased study of randomly selected older people living in 2 cities in the Chianti area, tuscany, italy, designed by the Laboratory of Clinical epidemiology of the italian research Council of aging (Florence) to identify risk factors for late-life disability, as previously described (10 using a multistage sampling method. in 1998, 1453 persons who were randomly selected from the population agreed to participate in the project. the italian national research Council on aging ethical Committee ratified the study protocol and participants provided written consent to participate. of the original 1453 subjects we excluded 298 participants younger than 65 years and 217 with no information on hormonal measures, or because refused physical examination or were too sick to be evaluated. the final study population included 938 older subjects (536 women and 402 men) with complete information on igF-1, igF-binding protein-1 (igFBP-1), igFBP-3 and medications. Demographic information on educational and marital status, smoking and medication use were collected using standardized questionnaires. Blood samples were collected in the morning after a 12-h fast. aliquots of serum and plasma were stored at 80°C. igF-1 was measured by immunoradiometric assay using commercial reagents. the Minimum Detectable Concentration (MDC) was 0.80 ng/ml. inter and intra-assay Coefficients of Variation (CV) were <10%. igFBP-1 and igFBP-3 were measured by immunoradiometric assay. Serum levels of interleukin-6 (iL-6), were measured in duplicate by high sensitivity enzyme-linked immunoabsorbent assays (eLiSa) using commercial kits (BioSourCe international, Camarillo, Ca). the MDC for iL-6 was 0.1 pg/ml. the interassay CV was less than 7%. Creactive protein (CrP) was measured in duplicate using an enzyme-linked immunosorbent assay and colorimetric competitive immunoassay with purified protein and polyclonal anti-CrP antibodies. the MDC was 0.03 mg/L and the interassay CV was 5%.
igF-1/igFBP-1 ratio as measure of igF-1 bioactivity was also calculated (11) .
Physical activity level in the previous year was considered as an ordinal variable and scored into seven progressive grades, from 0 (hardly any physical activity) up to 7 (intense exercise many times/week) by using a modified version of a standard questionnaire (12) 
Results
Participants were categorized according to PPi use. 35 subjects (14 men and 21 women), corresponding to 4% of the entire population, were identified as PPi users. the mean age of whole population was 75.7 ± 7.4 years ± SD. none of the participants were on gH treatment and corticosteroids. the group of PPi users had lower BMi, fasting glycemia, and were taking a greater number of medications when compared to nonusers (table 1) . PPi users had lower igF-1 levels than nonusers either after adjustment for age ( Figure 1 ) and age and sex (table 1) . PPi male users were older (77.7±7.5 vs 74.6±6.9) than male non-users, while women on PPi were younger than their non-users counterpart (74.2±4.8 vs 76.6±7.8) (data not shown). Figure 1 igF-1 serum levels in older PPi users (black column) and PPi non users (grey column) of both sexes. igF-1 levels were lower in PPi users than non users and the difference between two groups was statistically significant after adjustment for age after adjusting for age, male PPi users (107.0±69.6 vs 127.1±55.8 ng/ml, p<0.001) and female PPi users (87.6±29.1 vs 107.6±52.3 ng/ml, p=0.03) had lower levels of igF-1 than non-users (data not shown). PPi users and non-users had similar igFBP-1 levels, while igFBP-3 levels were almost significantly lower among PPi users.
JNHA: GERIATRIC SCIENCE
Multivariable analysis was carried out in the whole study population (table 2) . after adjusting for age, sex, BMi, albumin, liver function, CrP, iL-6, number of medications, aCe-inhibitors use, caloric intake, protein intake, physical activity, glycemia, and igFBP-1, the use of PPis remained significantly associated with igF-1 (β±Se=-19.60±9.83, p=0.045). the negative association between use of PPis and igF-1 was attenuated when igFBP-3 was included in the multivariable model (β±Se=-15.49±8.43, p=0.06) (data not shown). no significant association was found between PPi use and igFBP-1 and between PPi use and igF-1/igFBP-1 ratio (data not shown).
Discussion
in this preliminary analysis performed in older male and female population of the inCHianti study we found a negative association between PPi use and igF-1 levels.
this is the first human study addressing the relationship between PPi use and igF-1 system in older population.
these results are not surprising given the specific mechanism of action of these drugs. PPis, by inducing hypochlorhydria and reducing gastric proteolysis, decrease both adsorption and bioavailability of important nutrients and vitamins, worsening the overall nutritional status of older individuals (1).
Since igF-1 is not only an anabolic hormone but also a sensitive nutritional marker, the reduced levels of igF-1 in PPi users could be explained by the worse nutritional status in PPi group. in accordance with this hypothesis, PPi users had lower BMi (although in normal range) than non-users. However, the adjustment for BMi did not affect the relationship between PPi use and igF-1.
We also tested the levels of another nutritional marker such as albumin, but we failed to detect any significant difference between the two groups. an in vitro study shows that omeprazole, a PPi very commonly used, may affect igF bioactivity by enhancing igFBP-1 expression (9). in our study no significant difference in igFBP-1 levels was observed in PPi users and non users suggesting that mechanisms other than igFBP-1 should be explored to explain the difference in igF-1 levels in the two groups. interestingly, the relationship between PPi use and igF-1 levels was independent of age and sex and remained statistically significant when separate analyses in men and women were performed or when CrP, iL-6, physical activity, glycemia, protein intake, and medications known to increase igF-1 levels such as aCe-inhibitors were accounted (13, 14) .
We should acknowledge some limitations in our study. the group on PPi treatment was composed of a small number of subjects (n=35). information on type and duration of PPi treatment, PPi dosage was not available. the cross sectional nature of the analysis does not allow to infer any causality in the association between PPi use and igF-1 levels. Despite the presence of these limitations, this is the first evidence of the relationship between PPi use and igF-system in a population study. Complete information on igF-1 and igFBP-3 and inflammatory markers was available to test this very novel hypothesis.
in conclusion, use of PPi was independently and negatively associated with igF-1 levels in older italian men and women suggesting one of the potential mechanisms by which use of PPi can increase adverse outcomes in older subjects.
